NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing and distribution partner Alvogen Pine Brook LLC, has received tentative approval for our Abbreviated New Drug Application (ANDA) for Ibrutinib Tablets 560mg, 420mg, 280mg and 140mg strengths (generic for IMBRUVICA), from the U.S. Food and Drug Administration (USFDA).

Based on our ANDA filing date and the approval timeline, NATCO believes that we are eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product

at the time of launch.

As per industry sales data, IMBRUVICA (Tablet and Capsule dosage forms) had generated annual sales of $3.7 billion during the twelve months period ending December 2020 in the US market, of this, all the

strengths of IMBRUVICA Tablets alone generated sales of $3.0 billion during the same period.

Contact:

Natco Pharma Limited

Registered Office and

Corporate Headquarters

Natco House

Road No.2, Banjara Hills

Hyderabad-500 034, India

T: +91-40-2354 7532

T: +91-40-2354 5298/23548243

Website: www.natcopharma.com

(C) 2021 Electronic News Publishing, source ENP Newswire